Company: INDP
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001641172-25-010099
Chunk: 1

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Part I, Item 8
Chunk 1
---
by Equity Purchase Agreement. For more details, see Note 6(c). However, there is no assurance that additional
capital and/or financing will be available to the Company, and even if available, whether it will be on terms acceptable to the
Company or in the amounts required. If the Company is unsuccessful in securing sufficient financing, it may need to delay, reduce,
or eliminate its research and development programs, which could adversely affect its business prospects, or cease operations.

As a result of these uncertainties, there is
substantial doubt about the Company’s ability to continue as a going concern. The unaudited condensed consolidated financial
statements do not include any adjustments to the carrying amounts and classifications of assets and liabilities that would result if
the Company was unable to continue as a going concern.

NOTE 2: SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The unaudited interim condensed consolidated financial
statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America
(“US GAAP”) and SEC Regulation S-X Article 10 for interim financial statements. Accordingly, they do not contain all the information
and notes required by US GAAP for annual financial statements. In the opinion of management, these unaudited condensed consolidated interim
financial statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company’s
consolidated financial position as of March 31, 2025, and the consolidated results of operations and changes in stockholders’ equity
for the three-month periods ended March 31, 2025 and 2024 and cash flows for the three-month periods ended March 31, 2025 and 2024.

    F-5

These unaudited interim condensed consolidated financial
statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s
Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the SEC on March 13, 2025. The consolidated
balance sheet data as of December 31, 2024, included in these unaudited condensed consolidated financial statements was derived from the
audited financial statements for the year ended December 31, 2024, but does not include all disclosures required by US GAAP for annual
financial statements.

The results for the three-month period ended March
31, 2025, are not necessarily indicative of the results expected for